IP Library Granted Patent US 6,884,422
Granted Patent B1
US 6,884,422 · App. 09/807,783 · Granted Apr 26, 2005

Freeze-dried hepatitis A attenuated live vaccine and its stabilizer

Assignee: Changchun Institute of Biological Products, Ministry of Public Health
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,884,422
App. No.
09/807,783
Granted
Apr 26, 2005
Kind
B1
Abstract

The present invention relates to hepatitis A vaccine, especially to a lyophilized attenuated hepatitis A vaccine which can be stored at ambient temperature for extended periods of time, and to a method for producing the same. The present invention further relates to a stabilizer for lyophilized live vaccine and its use in improving thermostability of lyophilized live vaccine during lyophilization processing and storage period after lyophilization.

Claims (13)

1. A stabilized lyophilized hepatitis A live vaccine formulation comprising prophylactically effective titers of live attenuated hepatitis A virus and a stabilizer, wherein said live attenuated hepatitis A virus is prepared from the wild-type HAV, strain L-A-I, and wherein said stabilizer is present in the vaccine formulation at a concentration sufficient to stabilize the hepatitis A virus against heat inactivation.

2. A stabilized lyophilized hepatitis A live vaccine formulation according to claim 1 , wherein said stabilizer for lyophilized live hepatitis A virus comprises human serum albumin or gelatin or both of them; trehalose; at least one amino acid selected from the group consisting of glutamic acid, aspartic acid, arginine, lysine, and alkali metal salts of any of the foregoing; ascorbic acid; area; mannitol or sorbitol or both of them; and inositol.

3. A stabilized lyophilized hepatitis A live vaccine formulation according to claim 1 , wherein said stabilizer for the lyophilized live virus comprises from 0 to 20 grams per liter of human serum albumin, from 5 to 10 grams per liter of gelatin, from 50 to 100 grams per liter of trehalose, from 7.5 to 15 grams per liter of sodium glutamate, from 0.5 to 5.5 grams per liter of ascorbic acid, from 5 to 28 grams per liter of urea, from 2 to 10 grams per liter of mannitol or sorbitol, and from 4 to 10 grams per liter of inositol.

4. A method of preparing stabilized lyophilized live hepatitis A vaccine formulation according to claim 1 , comprising:

(a) providing a stock suspension of attenuated live Hepatitis A virus, wherein said live attenuated hepatitis A virus is prepared from the wild-type HAV, strain L-A-I;

(b) adding a stabilizer solution to stock suspension of attenuated live hepatitis A virus obtained from step (a) at the ratio 1:1 (v/v) to obtain a live vaccine formulation comprising prophylactically effective titers of live attenuated hepatitis A virus and a stabilizer for attenuated live virus, wherein said stabilizer comprises gelatine; trehalose; at least one amino acid selected from the group consisting of glutamic acid, aspartic acid, arginine, lysine, and alkali metal salts of any of the foregoing; ascorbic acid; urea; mannitol or sorbitol or both of them; and inositol; and

(c) lyophilizing said vaccine formulation obtained from the step (b).

5. The method according to claim 4 , wherein said lyophilizing step comprises pre-cooling the vaccine formulation to about −20° C. to −50° C. for about 3 to 6 hours, then drying the live vaccine formulation by gradually increasing the temperature to at least 32° C. in a lyophilizer.

6. The method according to claim 4 , wherein said stabilizer comprises from 0 to 20 grams per liter of human serum albumin, from 5 to 10 grams per liter of gelatin, from 50 to 100 grams per liter of trehalose, from 7.5 to 15 grams per liter of sodium glutamate, from 0.5 to 5.5 grams per liter of ascorbic acid, from 5 to 28 grams per liter of urea, from 2 to 10 grams per liter of mannitol or sorbitol, and from 4 to 10 grams per liter of inositol.

7. The method according to claim 4 , wherein said lyophilizing step comprises pre-cooling the vaccine formulation to about −20° C. to −50° C. for about 3 to 6 hours, then drying the live vaccine formulation by gradually increasing the temperature to at least 32° C. in a lyophilizer; and wherein said stabilizer comprises from 0 to 20 grams per liter of human serum albumin, from 5 to 10 grams per liter of gelatin, from 50 to 100 grams per liter of trehalose, from 7.5 to 15 grams per liter of sodium glutamate, from 0.5 to 5.5 grams per liter of ascorbic acid, from 5 to 28 grams per liter of urea, from 2 to 10 grams per liter of mannitol or sorbitol, and from 4 to 10 grams per liter of inositol.

8. A stabilizer for lyophilized live virus, wherein said stabilizer comprises gelatin; trehalose; at least one amino acid selected from the group consisting of glutamic acid, aspartic acid, arginine, lysine, and alkali metal salts of any of the foregoing, ascorbic acid; urea; mannitol or sorbitol or both of them; and inositol.

9. A stabilizer according to claim 8 , wherein said stabilizer comprises from 0 to 20 grams per liter of human serum albumin, from 5 to 10 grams per liter of gelatin, from 50 to 100 grams per liter of trehalose, from 7.5 to 15 grams per liter of sodium glutamate, from 0.5 to 5.5 grams per liter of ascorbic acid, from 5 to 28 grams per liter of urea, from 2 to 10 grams per liter of mannitol or sorbitol, and from 4 to 10 grams per liter of inositol.

10. A stabilizer according to claim 8 , wherein said lyophilized live virus is selected from the genus Enterovirus.

Assignments (2)
CHANGE OF NAME Recorded Dec 6, 2011
From: CHANGCHUN INSTITUTE OF BIOLOGICAL PRODUCTS, MINISTRY OF PUBLIC HEALTH
To: CHANGCHUN INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.
Reel/Frame 027330/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2002
From: LIU, JINGYA; WANG, PENGFUL; LI, GUANGPU; XIE, BAOSHENG; SONG, ZONGMING; LI, SHUYAN; LIU, JING; YU, YING; ZHANG, XIZHEN; LIANG, BEN; LIU, LINGJIU; WANG, WEI; ZHANG, LING; XUE, YONG; LI, JING; LI, YUHONG; LIN, HUI; WAN, ZONGJU
To: CHANGCHUN INSTITUTE OF BIOLOGICAL PRODUCTS
Reel/Frame 013121/0969 →
Priority Claims (1)
CN 98120633 A · Oct 19, 1998 · national